BeautyHealth Stock Receives Mixed Analyst Outlook Amid Recent Gains

Beauty Health Co shares are trading slightly higher in early market activity, buoyed by fresh commentary from financial analysts. While the overall sentiment remains cautious, some firms are pointing to potential recovery signs for the specialty aesthetics company.

Roth Capital Initiates Coverage with Bullish Stance

Expressing notable confidence, Roth Capital commenced coverage of Beauty Health on Friday with a Buy recommendation. Analyst George Kelly set a price target of $3.50, citing the company’s successful management restructuring and financial estimates he views as overly conservative. The firm anticipates that cost-saving initiatives and new product launches scheduled for late 2025 and 2026 will provide significant momentum.

TD Cowen Maintains Caution Despite Target Increase

In a contrasting move, TD Cowen adjusted its valuation on Tuesday, raising the price objective from $2.00 to $2.50. This 25 percent increase suggests a potential 7.5 percent upside from Monday’s closing price. However, analyst Oliver Chen reaffirmed a Hold rating on the stock, indicating lingering skepticism about the near-term outlook.

Should investors sell immediately? Or is it worth buying Beauty Health Co?

Stock Performance and Market Context

The equity concluded Monday’s session with a 2.2 percent advance at $2.33, albeit on light trading volume. Currently, the stock is trading in the upper segment of its 52-week range, which spans from $0.78 to $2.69. The critical question for investors is whether Beauty Health can maintain this positive trajectory. While the company’s most recent quarterly results in August exceeded expectations and prompted an upward revision of its annual forecast, the share price has previously demonstrated sensitivity to competitive developments.

The consensus price target from six covering analysts stands at $2.25, closely aligning with the current market price. A majority of the nine firms monitoring the stock continue to advise a Hold position. The success of upcoming product releases is widely seen as the key factor that could convert prevailing market caution into sustained confidence.